pharmaphorum

AUGUST 10, 2021

million for the one-shot therapy, which was approved in 2019 but faced a delayed launch because of manufacturing problems. At the time, the biotech said it would also reduce staff and restructure its European business in order to focus on “priority” markets. bluebird had set an initial price of $1.8

Gene Therapy 135

Gene Therapy Gene Marketing Genetic Disease 135

Roots Analysis

FEBRUARY 21, 2022

Since the introduction of a gene sequencing method by Frederick Sanger in 1977, the field of genomic data collection and analysis has evolved significantly. Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Roots Analysis

FEBRUARY 23, 2022

Further, NGS library preparation kits offer several benefits, such as low requirement of starting material, generation of longer RNA / DNA sequences and production of superior quality nucleotide libraries, thereby, catering to existing unmet needs of the research domain. Next Generation Sequencing (NGS) Library Preparation Kits.

Genetics 52

Genetics DNA RNA Reagent 52

Pharmaceutical Technology

MAY 26, 2023

Enzymatic DNA production company Touchlight have augmented its DNA production capabilities with a newly announced expansion to its London facilities. Tripling its production capacity, Touchlight can now manufacture 8kg plasmid DNA, a key component for mRNA gene therapies and vaccines.

DNA 130

DNA Manufacturing Gene Gene Therapy 130

Roots Analysis

OCTOBER 16, 2023

DNA cloning refers to the process of generating multiple copies of a particular DNA segment. DNA and Gene Cloning involves the isolation of a DNA sequence of any species ( often a gene ) and its insertion into a vector to enable growth without any alteration in the original DNA sequence.

DNA 40

DNA Gene Protein In-Vitro 40

pharmaphorum

OCTOBER 1, 2021

Shares in DNA sequencing specialist Oxford Nanopore rocketed after the company made its debut on the London Stock Exchange yesterday, rising nearly 50% to propel its valuation up towards the £5 billion ($6.7 billion) mark.

Marketing 52

Marketing Genome Genomics Business Development 52

pharmaphorum

JANUARY 5, 2023

The company develops mRNA therapeutics and vaccines , and the move will enable it to utilise the synthetic biology and enzyme tech of 2018-founded Japanese company OriCiro, which develops cell-free DNA synthesis and amplification technologies, and thereby expand Moderna’s portfolio.

Gene Sequencing 97

Gene Sequencing DNA Vaccination Vaccine 97